



BC Centre for Disease Control
Provincial Health Services Authority

Communicable Diseases and Immunization Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: January 14, 2022

Administrative Circular: 2022:03

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products**

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

Footnote C has been added to booster doses to indicate that pregnant persons may receive a booster dose at least 8 weeks after completion of a primary COVID-19 vaccine series.

Please remove page numbers: 1-2 dated January 7, 2022
Please add new page numbers: 1-2 dated January 14, 2022

COVID-19 mRNA Vaccine COMIRNATY® (Pfizer-BioNTech) (Adult/Adolescent)

- **Doses and Schedule:**
 - The Health Canada authorized interval of 21 days between dose 1 and 2 has been moved to Footnote C and the preferred interval of 8 weeks has been moved in its place under DOSES AND SCHEDULE.
 - The recommendation that the vaccine series should be completed with the same COVID-19 vaccine product has been removed from the footnotes.
 - Footnote G has been revised to indicate that the 8 week minimum interval from completion of the primary series to a booster dose applies to pregnant persons.

Please remove page numbers: 1-6 dated December 31, 2021
Please add new page numbers: 1-6 dated January 14, 2022

COVID-19 mRNA Vaccine COMIRNATY® (Pfizer-BioNTech) (Pediatric)

- **Doses and Schedule:**
 - The Health Canada authorized interval of 21 days between dose 1 and 2 has been moved to Footnote C and the preferred interval of 8 weeks has been moved in its place under DOSES AND SCHEDULE.
- **Administration:**
 - Footnote B has been added to indicate that the date printed on the vial and carton is the date of manufacture and that the vaccine must be used within 6 months of this date when stored at -90°C to -60°C.

Please remove page numbers: 1-5 dated December 15, 2021
Please add new page numbers: 1-5 dated January 14, 2022

COVID-19 mRNA Vaccine SPIKEVAX (Moderna)

- **Doses and Schedule:**
 - The Health Canada authorized interval of 28 days between dose 1 and 2 has been moved to Footnote C and the preferred interval of 8 weeks has been moved in its place under DOSES AND SCHEDULE.
 - The recommendation that the vaccine series should be completed with the same COVID-19 vaccine product has been removed from the footnotes.
 - Footnote G has been revised to indicate that the 8 week minimum interval from completion of the primary series to a booster dose applies to pregnant persons.
- **Administration:**
 - Footnote C has been updated to include content regarding the recent 2 month shelf life extension for certain lots of Moderna COVID-19 mRNA vaccine with expiry dates of February 15, 2022 through August 31, 2022. The new expiry dates can be found in the [Health Canada alert](#).

Please remove page numbers: 1-5 dated December 31, 2021
Please add new page numbers: 1-5 dated January 14, 2022

COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

- **Administration:**
 - Content has been revised to include frozen storage time and duration at -25°C to -15°C. Guidance regarding thawing parameters has also been included.

Please remove page numbers: 1-4 dated January 7, 2022
Please add new page numbers: 1-4 dated January 14, 2022

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,



Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health &
Wellness, PHSA & Deputy Provincial
Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population &
Public Health Division:

Brian Sagar
Senior Director Communicable
Disease, Population and Public Health
Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division